TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
TECH

Bio-Techne Corp

Healthcare · Biotechnology

72.40$ -0.1% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios TECH
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
Valuation
44.7 55.1 55.7 68.5 85.4 73.1 70.7 109.3 111.5 113.8 74.9 61.0
9.6 10.8 9.8 9.9 11.0 9.7 7.7 6.6 7.1 7.6 6.8 9.1
5.5 6.3 5.6 5.6 6.0 5.6 4.6 4.2 4.4 4.6 3.9 5.3
9.9 11.1 10.0 10.1 11.1 9.8 7.9 6.7 7.3 7.7 6.8 9.1
27.4 33.7 32.1 37.4 43.2 38.1 33.7 37.9 40.0 41.1 31.8 32.2
51.2 54.8 45.0 48.8 52.5 45.5 42.2 31.3 38.8 41.4 30.4 42.2
2.0% 1.8% 2.2% 2.0% 1.9% 2.2% 2.4% 3.2% 2.6% 2.4% 3.3% 2.4%
Margins
67.8% 67.1% 66.8% 66.4% 65.5% 65.6% 65.8% 64.8% 65.4% 65.2% 65.0% 65.8%
26.1% 23.5% 22.1% 17.8% 16.3% 16.7% 14.2% 8.4% 9.0% 9.6% 12.7% 20.7%
21.6% 19.6% 17.6% 14.5% 12.9% 13.2% 10.9% 6.0% 6.4% 6.7% 9.0% 15.0%
18.8% 19.7% 21.8% 20.4% 20.9% 21.3% 18.3% 21.0% 18.4% 18.3% 22.3% 21.7%
Returns
12.3% 11.4% 10.1% 8.1% 7.0% 7.6% 6.5% 3.8% 4.0% 4.0% 5.3% 8.6%
9.0% 8.2% 7.5% 6.2% 5.5% 5.9% 5.0% 2.9% 3.1% 3.2% 4.3% 7.0%
Balance Sheet & Debt
304 330 262 180 126 136 203 198 169 101 4.4 -50
0.7 0.9 0.7 0.6 0.4 0.4 0.7 0.9 0.8 0.4 0.0 -0.1
72.5% 71.9% 74.0% 76.5% 78.2% 77.8% 76.3% 75.0% 77.8% 79.7% 81.8% 81.5%
0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1
Per Share
1.52 1.40 1.26 1.05 0.94 0.98 0.83 0.47 0.50 0.52 0.70 1.16
7.06 7.15 7.19 7.21 7.27 7.45 7.60 7.83 7.78 7.74 7.71 7.74
12.34 12.27 12.55 12.88 13.27 12.94 12.70 12.32 12.57 12.81 13.29 13.43
1.33 1.41 1.56 1.47 1.52 1.58 1.39 1.65 1.43 1.42 1.72 1.68

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?